Virtual cofactors for an Escherichia coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)

Antibody directed enzymes revive anti-cancer prodrugs concept

K D Bagshawe · British Journal of Cancer · 1987 · 278 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +12

A cytotoxic agent can be generated selectively at cancer sites

K D Bagshawe, Springer Cj, F Searle et al. · British Journal of Cancer · 1988 · 265 citations · Full text

Medicine, Cancer Biology, Oncology +11

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

Mark G. Saulnier, George J. Schreiber, David L. Hirschberg et al. · Proceedings of the National Academy of Sciences · 1988 · 235 citations · Full text

Medicine, Oncology, Pharmacology +17

The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—I

Gillian M. Anlezark, Roger G. Melton, Roger F. Sherwood et al. · Biochemical Pharmacology · 1992 · 215 citations

Life Sciences, Biochemistry, Medicinal Chemistry +3

A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cells

Richard J. Knox, Frank Friedlos, Michael Jarman et al. · Biochemical Pharmacology · 1988 · 166 citations

Medicine, Cancer Biology, Oncology +9